FDA accepts for priority review a Gilead Sciences supplemental BLA for Trodelv (sacituzumab govitecan-hziy) for treating certain adult patients with u...
FDA warns Mexicos Eksa Mills about CGMP violations in its manufacturing of finished drugs.
Federal Register: FDA revokes an emergency use authorization issued to Laboratorio Clinico Toledo, Puerto Rico, for its Laboratorio Clinico Toledo SAR...
Regeneron Pharmaceuticals and Sanofi say they will seek FDA approval next year for Dupixent (dupilumab) and its use in treating children with active e...
Federal Register notice: FDA makes available a draft guidance entitled Facility Readiness: Goal Date Decisions Under GDUFA.
FDA sends Supernus Pharmaceuticals a complete response letter on its NDA for SPN-830 (apomorphine) infusion device for the continuous treatment of mot...
Merck reports positive top-line results from a pivotal Phase 3 trial (STELLAR) evaluating the safety and efficacy of sotatercept, an investigational d...
Federal Register notice: FDA announces the fee rate for using a priority review voucher for fiscal year 2023.
